Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Dropped Today

By Prosper Junior Bakiny – Jul 23, 2020 at 5:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One analyst isn’t particularly bullish on Moderna.

What happened?

Shares of Moderna (MRNA -0.58%) declined sharply on Thursday and ended the trading session down by 9.6%, despite the company not reporting any news. The catalyst for the biotech's losses on the market today may have been negative comments from an analyst. 

So what

In a note issued Wednesday evening, SVB Leerink analyst Mani Foroohar initiated coverage on Moderna's stock with a market perform (or "hold") rating. The analyst also gave the stock a $65 price target. Note that even after today's decline, Moderna's shares are worth $75.33 apiece. Foroohar believes that Moderna's experimental vaccine for COVID-19, mRNA-1273, has good chances of earning regulatory approval.

Further, the analyst sees Moderna attracting a lot of patients with its vaccine in the early days after it is launched. Despite these potential upsides, Foroohar thinks Moderna's stock is currently overvalued and sees its current levels as an "unattractive risk/reward to investors following torrid performance year-to-date."

Road sign that says "risk ahead."

Image source: Getty Images.

Now what

Foroohar may be onto something; Moderna's shares have soared by a little more than 280% this year, mainly due to its efforts to develop a vaccine for COVID-19. Sure, the company seems increasingly likely to launch its vaccine on the market, especially given that it plans on starting a phase 3 clinical trial for mRNA-1273 on Jul. 27. Still, several competitors -- including Pfizer and AstraZeneca -- are also making significant headway in their efforts.

What's more, given the dire worldwide need for a COVID-19 vaccine, several companies could end up getting their candidates approved by regulatory authorities. Moderna may have to share this market with its peers, and in the long run, the financial benefits it will reap from this opportunity may not live up to investors' expectations. For all these reasons, this biotech stock seems a bit too risky. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$175.38 (-0.58%) $-1.02
Pfizer Stock Quote
Pfizer
PFE
$49.57 (0.73%) $0.36
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.21 (0.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.